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Abstract
The aim of our study was to test the hypothesis that the spatial distribution of breast cancer
brain metastases (BM) differ according to their biological subtypes. MR images of 100
patients with BM from primary breast cancer were retrospectively reviewed. Patients were
divided according to the biological subtype of the primary tumor, (triple-negative: 24, HER2
positive: 48, luminal: 28). All images marked with BMs were standardized to the human
brain MRI atlas provided by the Montreal Neurological Institute 152 database. Distribution
pattern of BM was evaluated with intra-group and intergroup analysis. In intra-group analy-
sis, hot spots of metastases from triple-negative are evenly distributed in the brain, mean-
while BMs from HER2 positive and luminal type occur dominantly in occipital lobe and
cerebellum. In intergroup analysis, BMs from triple-negative type occurred more often in
frontal lobe, limbic region, and parietal lobe, compared with other types (P < .05). Breast
cancer subtypes tend to demonstrate different spatial distributions of their BMs. These find-
ings may have direct implications for dose modulation in prophylactic irradiation as well as
for differential diagnoses. Thus, this result should be validated in future study with a larger
population.
Introduction
Brain metastases (BMs) are the most commonly encountered malignant tumors occurring in
the CNS, outnumbering primary CNS tumors by more than 10-fold[1]. Breast cancer is the
second most frequent cause of BM after lung cancer, with metastases occurring in 10–16% of
patients[2]. Median survival ranges from 3 to 15 months following metastatic spread to the
brain, making BMs one of the major causes of systemic cancer-related mortality[3]. Recently,
the incidence of BMs has increased because of improvements in treatment for primary cancers
and more advanced imaging techniques[4,5].
Breast cancer can be divided into several biologic subtypes on the basis of their clinical, his-
topathological, and molecular features. Further, breast cancer can be classified on the basis of
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their gene expression profiles into luminal, basal, and HER2-positive, with each subtype show-
ing a clearly different prognostic significance[6,7]. The subgroups of patients with triple-nega-
tive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a
higher risk for development of BMs[8–10]. The onset of BMs in triple receptor-negative breast
cancer is earlier than that observed in other subtypes, and the overall survival rate is particu-
larly poor, when compared to other subtypes[11].
Treatment options for patients with breast cancer BMs are limited and include surgical
resection, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy, and tar-
geted therapy[12–14]. Prophylactic cranial irradiation improves the survival rate of patients
with lung cancer BMs[15,16], and may represent a novel approach for select patients with
breast cancer BMs[17]. Thus, understanding the spatial distributions of BMs by breast cancer
subtype may allow for more precise prophylactic irradiation adjustments and could lead to the
development of novel targeted therapy.
Biological characteristics of tumors could affect the spatial distribution of their BMs. For
example, the probability of cerebellar metastases is higher in lung and breast cancer[18]. BMs
are typically located in watershed areas such as the gray-white matter junction[19]. Recently,
Takano et al. reported that lung cancer BMs with an epidermal growth factor receptor (EGFR)
L858R mutation occurred more often in the caudate nucleus, cerebellum, and temporal lobe
than those with an EGFR exon 19 deletion[20]. We hypothesized that breast cancer BMs have
different spatial distributions according to their biological subtypes.
Materials and methods
Participants
We retrospectively reviewed data for breast cancer patients with BM who underwent gado-
linium-enhanced brain MRI from 2009 to 2016. A total of 128 patients were identified. Of
theses 27 patients were excluded for the following reasons (Fig 1): (1) previous neurosurgery
or brain radiation therapy (n = 10); (2) presence of other malignant disease (n = 5); and
(3) absence of the immunohistochemistry profile of breast cancer (n = 12). A total of 101
patients was remained after selection criteria. However, an unknown error occurred during
exporting from the hospital database to the local computer in one of 101 brain MRIs, and
this case was removed in the statistical mapping. Finally, gadolinium-enhanced 3D T1WIs
of 100 breast cancer patients in whom BMs were initially diagnosed were included in this
analysis (slice thickness <1.5 mm on 3.0T MRI). Patients were divided into three groups
according to biological subtypes on the basis of the expression of estrogen (ER), progester-
one (PgR), and HER2. Immunohistochemistry was carried out for the evaluation of the
level of ER, PgR, and HER2 expression of primary breast cancer. Florescence in-situ hybrid-
ization analysis of HER2 amplification was carried out in immunohistochemistry 2+ cases.
The three subtypes were triple negative (ER-, PgR-, HER2-), HER2 positive (HER2(+), any
ER/PgR), and luminal (ER/PgR(+), HER2(-)). The current study design and use of clinical
data was approved by the institutional review board of Gangnam Severance hospital The
requirement to obtain informed consent was waived, and all data were fully anonymized.
Image registration and frequency map reconstruction
DICOM gadolinium-enhanced 3D T1WIs were reviewed by Two radiologist (A.S.J, S.S.H) to
identify the focus of the brain metastases. They independently marked brain metastases and
recorded coordinates (x,y,z) of brain metastases. Interobserver agreement was assessed using
the Concordance Correlation Coefficient (CCC). The coordinates of reader 1 was used for fur-
ther analysis. Fig 1 presents the flowchart for mapping brain metastases (BMs) in the
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standardized automated anatomical labeling (AAL) template space[21]. The primary sites of
occurrence were then individually mapped in Neuroimaging Informatics Technology Initia-
tive format by assigning ones for the manually identified lesions and zeros otherwise (Fig 1A).
After converting DICOM images to the Neuroimaging Informatics Technology Initiative for-
mat using the dcm2nii software (http://cabiatl.com/mricro/mricron/dcm2nii.html), the
images were normalized to the standard space using the Statistical Parametric Mapping
(SPM12; http://www.fil.ion.ucl.ac.uk/spm/software/spm12) software. Individually coregistered
images of the BMs and a manually marked lesion map were standardized to the human brain
MRI atlas provided by the Montreal Neurological Institute (MNI) 152 database with a 1×1×1
mm voxel size. For frequency map reconstruction, normalized lesion maps were extended to a
site-centered spherical shape with a radius of 15 mm (Fig 1B). Subsequently, these spherical
BMs were matched with the AAL template. Initially, we assigned zeros for 116 cortical, subcor-
tical, and cerebellar regions in AAL template space, we then assigned ones if there were over-
laps between individual spherical BMs and AAL regions. Finally, all BM heat maps were
reconstructed and superimposed in the AAL space to determine the frequency of metastasis
occurrence (Fig 1C).
Analysis of spatial distribution of brain metastasis
For intra-group analysis, heat map is generated based on the percentage of brain metastasis
involving specific AAL region, which was defined as number of patients whose brain metasta-
sis involving specific AAL region per total number of patients with a specific breast cancer sub-
type. Top10% of ALL regions in frequency of metastases could be listed using heat map. For
intergroup analysis, the frequency of occurrence of metastasis was compared between biologi-
cal subtypes of the breast cancer: (1) triple-negative or non-triple-negative; (2) HER2 or non-
HER2; and (3) luminal or non-luminal. Single-subject BM maps were entered into a second-
level analysis using a χ2 test crosstab analysis to assess group level significance. The signifi-
cance threshold was set at P< .05
Fig 1. Flowchart for mapping brain metastases (BMs) in the standardized automated anatomical labeling (AAL) template space. The center
coordinates of BMs in the native space were identified by a trained radiologist (A). The individual center coordinates of BMs were normalized in the Montreal
Neurological Institute space and normalized lesion maps were extended to a site-centered spherical shape with a radius of 15 mm (B). The AAL template
was matched with the spherical BMs in the MNI space. We assigned 1 if there were overlaps between BM and AAL nodes (C). For examples, 1) if the center
coordinate of BM is located around the temporal regions and its spherical ROI with 15 mm radius were overlapped with the superior temporal gyrus and
middle temporal gyrus, then those two temporal gyri were identified as neighbor nodes (top image of Fig 1C). 2) if the center coordinate of BM is located
around the paracentral lobule and the middle cingulate gyrus and its spherical ROI with 15 mm radius were overlapped with the middle cingulate gyrus,
paracentral lobule, supplementary motor area, and precuneus, then these four medial regions were identified as neighbor nodes (bottom image of Fig 1C).
https://doi.org/10.1371/journal.pone.0188542.g001
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Results
In total, 100 patients were analyzed: 24 patients had triple-negative breast cancer, 48 patients
had HER2-positive breast cancer, and 28 patients had luminal breast cancer. All patients were
female. Age at initial diagnosis of breast cancer was not significantly different among breast
cancer subtypes (46.45 ± 10.88 for triple-negative, 49.5 ± 11.45 for HER2, 46.75 ± 9.73 for
luminal; P = 0.26). Number of brain metastases per patient did not significantly differ by sub-
type (5.33 ± 5.78 for triple-negative, 4.71 ± 6.58 for HER2, 5.35 ± 6.69 for luminal; P = 0.88).
However, triple-negative and HER2-positive breast cancer showed a shorter time interval
until the onset of BMs than luminal breast cancer (23.5 ± 23.36 months for triple-negative,
19 ± 29.54 months for the HER2 subtype, and 42 ± 45.51 months for luminal subtype; P< .01,
Table 1)
Interobserver agreement
The coordinates of brain metastases had good reproducibility between two radiologists. Their
Concordance Correlation Coefficient was 0.996 (0.994–0.997)
Frequency map of brain metastases in each subtype (intra-group
analysis)
Fig 2 and Fig 3 show frequency of occurrence of brain metastases in each subgroup. Top 10%
regions in which metastases frequently occurred are evenly distributed in triple-negative,
whereas BMs are concentrated in occipital, temporal lobe and cerebellum for HER2-positive,
and in frontal, occipital lobe and cerebellum for luminal type.
Comparison of distribution of brain metastases according to their
subtypes (intergroup analysis)
BMs from triple-negative type breast cancer occurred more often in frontal lobe, limbic region,
and parietal lobe, compared with other subtypes (corrected P< .05). BM from HER2-positive
occurred less frequently in frontal lobe and subcortical region. BM from luminal type occurred
less frequently in occipital lobe, subcortical region and cerebellum (corrected P< .05).
Discussion
In this study, we evaluated the spatial distributions of BMs by breast cancer subtypes. We
found that metastases from triple-negative breast cancer spread evenly in brain, but in case of
HER2-positive and luminal types, BMs are concentrated in posterior circulation territories
such as occipital lobe and cerebellum. In addition, compared with other subtypes, BMs from
triple negative occur more frequently in frontal lobe, limbic region, and parietal lobe. The
Table 1. Patient characteristics.
All cancers Triple negative
(ER-, PgR, HER2-)
HER2
(HER2+, any ER/
PgR)
Luminal
(ER/PgR+, HER2-)
P-value
Patients (n) 100 24 48 28
Female (n) 100 24 48 28
Age (year) at diagnosis of primary tumor 47 ± 10.91 46.45 ± 10.88 49.5 ± 11.45 46.75 ± 9.73 .26
Duration between primary tumor and brain metastases
(months)
22 ± 35.01 23.5 ± 23.36 19 ± 29.54 42 ± 45.51 < .01
Number of brain metastases per patient 5.04 ± 6.37 5.33 ± 5.78 4.71 ± 6.58 5.35 ± 6.69 .88
https://doi.org/10.1371/journal.pone.0188542.t001
Different spatial distribution of brain metastasis in different subtypes of breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0188542 November 20, 2017 4 / 10
clinical implication of this observation is important because prophylactic irradiation with dose
modulation to the preferential site is a viable approach for breast cancer to enhance its preven-
tive effect and reduce any side effects.
Several studies have found that the cerebellum was the predominant site of metastases in
breast cancer patients.[22–24] Our data also confirm that the cerebellum is the preferential site
of breast cancer BMs. Conventionally, the “seed and soil theory” has been used to explain the
preferential involvement of specific areas within the brain: the site of metastasis depends on the
affinity of the tumor (the “seed”) to the microenvironment (the “soil”)[25]. Other potential
explanations for preferential involvement of the cerebellum are as follows: (1) high gyral density
Fig 2. Heat maps of brain metastases (BMs). Overlapping of BMs across all patients with breast cancer (A), patients with triple negative type (B),
patients with HER2+ type (C), and patients with Luminal type (D). Color-bars indicate the percentage of BMs. Abbreviations: CBL, cerebellum; IFG,
inferior frontal gyrus; MFG, middle frontal gyrus; L, left; R, right; MO, middle occipital; PMC, premotor cortex.
https://doi.org/10.1371/journal.pone.0188542.g002
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Fig 3. The percentages of BMs were plotted across all patients (A), patients with triple negative gene
type (B), patients with HER2+ gene type (C), and patients with Luminal type (D). Brain regions were sorted
Different spatial distribution of brain metastasis in different subtypes of breast cancer
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of the cerebellar cortex compared to that of the cerebral hemispheres; (2) higher blood volumes
and longer perfusion times of the tissue per minute in posterior circulation territories[26,27];
(3) different regional vasomotor response in the cerebellar circulation oriented toward a greater
vessel dilatation[28,29].
However, recent studies have revealed the molecular mechanism of the spatial distribution
of BMs. In breast cancer, chemokine receptors such as CXCR4 and CCR7 play a critical role in
determining the metastatic destination of tumor cells[30]. COX2, EGFR ligand, and ST6GAL-
NAC5 cross over the blood-brain barrier and enhance breast cancer metastasis to the brain.
Evidence of specific subtypes showing a preference for brain metastasis is overwhelming. Tri-
ple-negative and HER2-positive breast cancer predispose to a higher risk of BM than that
observed in luminal breast cancer, with an incidence of 30–40%[31–33]. A previous study
reported that triple-negative type and HER2-positive breast cancer show an earlier onset of
BMs than luminal breast cancer, which is consistent with our study[11,34]. In a recent study,
WNT signaling was up-regulated in the triple-negative subtype and the BMs, but down-regu-
lated in the luminal subtype and bone metastases[35]. Thus, we can assume that the spatial dis-
tribution of BMs differ according to the genetic composition of the primary breast cancer.
Interestingly, our study showed that BMs of tripe-negative spread evenly in the whole brain,
however HER-2 positive and luminal types have preferential involvements in the posterior cir-
culation territories such as occipital lobe and cerebellum.
Despite neurosurgery and radiosurgery, triple-negative type breast cancer patients have the
worst prognosis, with an overall survival duration of only 4.9 months.[36] Prophylactic cranial
irradiation is a suitable treatment option for high-risk breast cancer. A randomized controlled
trial showed that among 62 high-risk breast cancer patients receiving prophylactic cranial irra-
diation with 24 Gy in 10 fractions over 2 weeks, none developed BMs, but 6.4% of patients in
the no prophylactic cranial irradiation arm developed BMs.[37] Thus, our results suggest dif-
ferent strategies of dose modulation of radiotherapy (whole brain coverage for triple-negative
vs posterior circulation territories for HER2+ and luminal type).
Our results also may increase the diagnostic yield of brain metastases. Clinical information
of triple-negative type of primary breast cancer could make radiologist to review, with a metic-
ulous effort, occipital lobe and cerebellum as well as frontal, limbic and parietal lobe.
This study has a limitation. The number of cases was not enough to draw a solid conclusion.
However, our results may serve as a cornerstone for future studies with a larger population to
validate and extend these results.
In conclusion, different breast cancer subtypes may show different spatial distributions of
BMs. Triple-negative breast cancer BMs has a tendency to spread evenly in the whole brain,
meanwhile HER2+ and luminal types have a preponderance for posterior circulation territo-
ries. These results suggest different strategies for prophylactic irradiation according to sub-
types (triple-negative vs other types).
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in the order of the frontal, limbic, occipital, parietal, subcortical (SubCor), temporal, and cerebellum. Brain regions
above dotted-line indicate the top 10% frequently occurring BMs. Reddish points indicate brain regions showing
significant group differences from χ2 test.
https://doi.org/10.1371/journal.pone.0188542.g003
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